News

Cantech Letter5d
OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients
OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease1 MISSISSAUGA, ON, /CNW/ – Alnylam Canada ULC is pleased to announce that ...